Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung Tsugumasa Kamata, MD, Kuniko Sunami, MD, Akihiko Yoshida, MD, PhD,

Slides:

Advertisements

Similar presentations

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Advertisements

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

SC17.02 Lung Cancer in China: Challenges and Perspectives

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

Clinicopathological and biological assessment of lung cancers with pleural dissemination Yasuhiko Ohta, MD, Yoko Tanaka, PhD, Takuo Hara, MD, Makoto.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer Kyohei Masai, MD, Hiroyuki Sakurai,

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Cavity Wall Thickness in Solitary Cavitary Lung Adenocarcinomas Is a Prognostic Indicator Yukio Watanabe, MD, Masahiko Kusumoto, MD, Akihiko Yoshida,

Experience with Erlotinib in Lung Adenocarcinoma Harboring a Coexisting KIF5B-RET Fusion Gene and EGFR Mutation: Report of a Rare Case Fumihiko Hirai,

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Bilateral Subdural Hematoma Associated with Central Nervous System Metastases from Lung Cancer Akito Hata, MD, Shiro Fujita, MD, PhD, Nobuyuki Katakami,

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

First Case of Combined Small-Cell Lung Cancer with Adenocarcinoma Harboring EML4- ALK Fusion and an Exon 19 EGFR Mutation in Each Histological Component

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method.

Iris Metastasis in Small-Cell Lung Carcinoma

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

A Primer on Health Economic Evaluations in Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Histological Scoring for Small Lung Adenocarcinomas 2 cm or Less in Diameter: A Reliable Prognostic Indicator Akiko Miyagi Maeshima, MD, Naobumi Tochigi,

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

Primary Lung Cancer Presenting with Gastrointestinal Tract Involvement: Clinicopathologic and Immunohistochemical Features in a Series of 18 Consecutive.

C-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas Koji Tsuta, MD, PhD, Yoshiki Kozu, MD, PhD, Takahiro.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?

Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer Yoon Hee Choi, MD,

Genetic Changes in Squamous Cell Lung Cancer: A Review

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma Tatsuji Mizukami, MD, Kouya Shiraishi, PhD, Yoko Shimada, MFSc, Hideaki Ogiwara,

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

European Lung Cancer Conference (ELCC) 2016 Organisation

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

A B3 Type-Thymoma in a 7-Year-Old Child with Myasthenia Gravis

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung Tsugumasa Kamata, MD, Kuniko Sunami, MD, Akihiko Yoshida, MD, PhD, Kouya Shiraishi, PhD, Koh Furuta, MD, PhD, Yoko Shimada, MFSc, Hitoshi Katai, MD, PhD, Shun-ichi Watanabe, MD, PhD, Hisao Asamura, MD, PhD, Takashi Kohno, PhD, Koji Tsuta, MD, PhD Journal of Thoracic Oncology Volume 11, Issue 2, Pages 261-265 (February 2016) DOI: 10.1016/j.jtho.2015.10.021 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 A representative image of ciliated muconodular papillary tumors with hematoxylin–eosin staining. The epithelial components of the lesions consisted of a mixture of ciliated columnar cells (arrow), mucous cells (asterisk), and basal cells (arrowhead). Journal of Thoracic Oncology 2016 11, 261-265DOI: (10.1016/j.jtho.2015.10.021) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 The results of the mutation analyses for 10 ciliated muconodular papillary tumors. Journal of Thoracic Oncology 2016 11, 261-265DOI: (10.1016/j.jtho.2015.10.021) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Immunohistochemical analyses of the BRAF-V600E ciliated muconodular papillary tumors. Each of the three epithelial components (i.e., ciliated columnar cells, mucous cells, and basal cells) exhibited cytoplasmic staining for BRAF-V600E. The monoclonal antibody also strongly cross-reacted with the cilia of the columnar cells (the internal positive control). Journal of Thoracic Oncology 2016 11, 261-265DOI: (10.1016/j.jtho.2015.10.021) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions